KR20160093731A - 뇌내 출혈을 치료하기 위한 조성물 및 방법 - Google Patents

뇌내 출혈을 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20160093731A
KR20160093731A KR1020167019778A KR20167019778A KR20160093731A KR 20160093731 A KR20160093731 A KR 20160093731A KR 1020167019778 A KR1020167019778 A KR 1020167019778A KR 20167019778 A KR20167019778 A KR 20167019778A KR 20160093731 A KR20160093731 A KR 20160093731A
Authority
KR
South Korea
Prior art keywords
less
ich
fxa
subject
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167019778A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 아킨
조아힘 프루비스
마커스 이. 카
서니타 헷
리마 자수자
데브라 디. 피트맨
Original Assignee
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화이자 인코포레이티드 filed Critical 화이자 인코포레이티드
Publication of KR20160093731A publication Critical patent/KR20160093731A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020167019778A 2014-01-24 2015-01-15 뇌내 출혈을 치료하기 위한 조성물 및 방법 Ceased KR20160093731A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461931071P 2014-01-24 2014-01-24
US61/931,071 2014-01-24
PCT/IB2015/050313 WO2015110939A1 (en) 2014-01-24 2015-01-15 Compositions and methods for treating intracerebral hemorrhage

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187002632A Division KR20180014221A (ko) 2014-01-24 2015-01-15 뇌내 출혈을 치료하기 위한 조성물 및 방법

Publications (1)

Publication Number Publication Date
KR20160093731A true KR20160093731A (ko) 2016-08-08

Family

ID=52630418

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020167019778A Ceased KR20160093731A (ko) 2014-01-24 2015-01-15 뇌내 출혈을 치료하기 위한 조성물 및 방법
KR1020217001254A Ceased KR20210008177A (ko) 2014-01-24 2015-01-15 뇌내 출혈을 치료하기 위한 조성물 및 방법
KR1020187002632A Ceased KR20180014221A (ko) 2014-01-24 2015-01-15 뇌내 출혈을 치료하기 위한 조성물 및 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020217001254A Ceased KR20210008177A (ko) 2014-01-24 2015-01-15 뇌내 출혈을 치료하기 위한 조성물 및 방법
KR1020187002632A Ceased KR20180014221A (ko) 2014-01-24 2015-01-15 뇌내 출혈을 치료하기 위한 조성물 및 방법

Country Status (18)

Country Link
US (2) US20160375109A1 (OSRAM)
EP (1) EP3096779B1 (OSRAM)
JP (1) JP6624787B2 (OSRAM)
KR (3) KR20160093731A (OSRAM)
CN (2) CN105934250A (OSRAM)
AU (1) AU2015208819B2 (OSRAM)
BR (1) BR112016014617A2 (OSRAM)
CA (1) CA2937418A1 (OSRAM)
DK (1) DK3096779T3 (OSRAM)
ES (1) ES2772802T3 (OSRAM)
HU (1) HUE047588T4 (OSRAM)
IL (1) IL246637A0 (OSRAM)
MX (1) MX375355B (OSRAM)
PL (1) PL3096779T3 (OSRAM)
PT (1) PT3096779T (OSRAM)
RU (1) RU2016126423A (OSRAM)
SI (1) SI3096779T1 (OSRAM)
WO (1) WO2015110939A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150103205A (ko) 2013-01-31 2015-09-09 화이자 인코포레이티드 인자 Xa 억제를 길항하기 위한 조성물 및 방법
SG11201601221XA (en) 2013-09-24 2016-04-28 Pfizer Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2570330A1 (en) * 2004-06-21 2005-12-29 Novo Nordisk Health Care A/S Use of factor viia or factor viia equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ich)
MX336958B (es) * 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
CN101918025A (zh) * 2008-01-18 2010-12-15 诺沃-诺迪斯克保健股份有限公司 因子Ⅶa或因子Ⅶa等同物用于防止或减弱选择的脑内出血患者亚群在脑内出血(ICH)后出血增多和/或水肿形成的用途
JP6163304B2 (ja) * 2009-07-15 2017-07-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子インヒビターの解毒剤の単位用量処方物およびその使用方法
WO2011020866A2 (en) * 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
US9371522B2 (en) * 2011-09-30 2016-06-21 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
SG11201500579SA (en) * 2012-07-25 2015-02-27 Catalyst Biosciences Inc Modified factor x polypeptides and uses thereof
KR20150103205A (ko) * 2013-01-31 2015-09-09 화이자 인코포레이티드 인자 Xa 억제를 길항하기 위한 조성물 및 방법

Also Published As

Publication number Publication date
PT3096779T (pt) 2020-02-21
CN105934250A (zh) 2016-09-07
IL246637A0 (en) 2016-08-31
JP6624787B2 (ja) 2019-12-25
ES2772802T3 (es) 2020-07-08
SI3096779T1 (sl) 2020-03-31
RU2016126423A (ru) 2018-03-01
KR20210008177A (ko) 2021-01-20
PL3096779T3 (pl) 2020-05-18
EP3096779B1 (en) 2019-12-18
DK3096779T3 (da) 2020-02-24
CN112156176A (zh) 2021-01-01
RU2016126423A3 (OSRAM) 2018-03-01
US20190231856A1 (en) 2019-08-01
CA2937418A1 (en) 2015-07-30
BR112016014617A2 (pt) 2017-09-19
US20160375109A1 (en) 2016-12-29
WO2015110939A1 (en) 2015-07-30
KR20180014221A (ko) 2018-02-07
MX2016009665A (es) 2016-11-14
AU2015208819A1 (en) 2016-06-30
EP3096779A1 (en) 2016-11-30
HUE047588T4 (hu) 2020-06-29
JP2015147764A (ja) 2015-08-20
HUE047588T2 (hu) 2020-04-28
AU2015208819B2 (en) 2020-01-23
MX375355B (es) 2025-03-04

Similar Documents

Publication Publication Date Title
JP6514893B2 (ja) 止血を調節するための組成物および方法
JP2019077677A (ja) 第Ｘａ因子の阻害を中和するための組成物および方法
US20160194623A1 (en) Novel mutated tissue plasminogen activators and uses thereof
KR101672108B1 (ko) 패혈증의 치료 및/또는 개선을 위한 의약
US20190231856A1 (en) Compositions and methods for treating intracerebral hemorrhage
CN113795274A (zh) 一种治疗肌萎缩侧索硬化的方法和药物
JP6629744B2 (ja) 第Ｘａ因子の半減期を延ばす組成物および方法
JP2022519327A (ja) 頭蓋内出血の治療方法及び効果の評価方法
HK40040435A (en) Compositions and methods for treating intracerebral hemorrhage
JP7237085B2 (ja) 凝固異常を伴う敗血症の治療及び／又は改善のための医薬
US20250302927A1 (en) Modified factor xa polypeptides and methods of use
HK1228257A1 (en) Compositions and methods for treating intracerebral hemorrhage
RU2818474C2 (ru) Гаптоглобин для применения в лечении неблагоприятного вторичного неврологического исхода после геморрагического инсульта
WO2026076443A1 (en) Methods for treating factor x deficiency
HK40059596A (en) Drug for treating and/or improving septicemia associated with coagulation abnormality
HK1196289B (en) Medicine for treatment and/or improvement of sepsis

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20160720

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170804

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180126

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180208

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170804

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I